XORTX Therapeutics Inc.
XRTX
$0.87
-$0.1026-10.55%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 2.41M | 2.39M | 2.35M | 2.40M | 2.40M |
Depreciation & Amortization | 115.40K | 106.00K | 105.00K | 139.70K | 137.90K |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 2.84M | 3.34M | 3.90M | 4.96M | 6.73M |
Operating Income | -2.84M | -3.34M | -3.90M | -4.96M | -6.73M |
Income Before Tax | -736.60K | -1.48M | -3.35M | -2.16M | -7.44M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -0.74 | -1.48 | -3.35 | -2.16 | -7.44 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -736.60K | -1.48M | -3.35M | -2.16M | -7.44M |
EBIT | -2.84M | -3.34M | -3.90M | -4.96M | -6.73M |
EBITDA | -2.76M | -3.25M | -3.83M | -4.83M | -6.61M |
EPS Basic | -0.04 | -0.50 | -1.41 | -1.11 | -4.09 |
Normalized Basic EPS | -0.02 | -0.31 | -0.88 | -0.70 | -2.55 |
EPS Diluted | -0.04 | -0.51 | -1.42 | -1.13 | -4.09 |
Normalized Diluted EPS | -0.02 | -0.31 | -0.88 | -0.70 | -2.55 |
Average Basic Shares Outstanding | 10.24M | 9.33M | 8.43M | 7.93M | 7.52M |
Average Diluted Shares Outstanding | 10.24M | 9.33M | 8.43M | 7.93M | 7.52M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |